Genetic loss of Prmt1 or pharmacological inhibition of PRMT1 remarkably blocked leukemia development, eliminated LSCs, and impaired the self‐renewal of LSCs in CML mice. This evidence concerns the gene PRMT1 and chronic myelogenous leukemia, BCR-ABL1 positive.